As CAR T-cell therapy has become a transformative option in multiple myeloma, a first-of-its-kind trial now extends that potential to relapsed/refractory light chain (AL) amyloidosis. At the recent ...

Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma-cell disorder present in approximately 5% of the general population over the age of 50 years. MGUS is characterized ...

We read with great interest the recent article by Tsai et al,1 which compared characteristics between primary neuromyelitis ...

Serum free light chain (sFLC) tests have advanced the prediction, diagnosis, and monitoring of plasma cell disorders. This webinar features two leading experts who will compare the performance of sFLC ...

Researchers show for the first time that engineered human plasma B cells can be used to treat a disease -- specifically leukemia -- in a humanized animal model. The results mark a key step in the ...

A single cilta-cel infusion after fludarabine/cyclophosphamide produced 100% MRD negativity at 10⁻⁶ by month 2, sustained at ...

Staging is when a system is used to identify and describe how far a cancer has spread in your body. Knowing the stage of your multiple myeloma helps your physicians predict which treatments are most ...

Discover how mapping plasma proteins to diseases in 53,000 adults is transforming diagnostics, advancing treatments, and paving the way for personalized healthcare solutions. Study: Atlas of the ...

Japanese clinicians have reported a rare case in which fibrillary glomerulonephritis (FGN) developed as a patient’s monoclonal gammopathy progressed to multiple myeloma. The 41-year-old man’s kidney ...

Researchers reveal critical mechanism behind idiopathic pulmonary fibrosis. Rutgers Health researchers have discovered that networks of misplaced immune cells drive an aggressive lung disease, ...